EP0868179A4 - Nouvelle utilisation du losartan - Google Patents

Nouvelle utilisation du losartan

Info

Publication number
EP0868179A4
EP0868179A4 EP96944328A EP96944328A EP0868179A4 EP 0868179 A4 EP0868179 A4 EP 0868179A4 EP 96944328 A EP96944328 A EP 96944328A EP 96944328 A EP96944328 A EP 96944328A EP 0868179 A4 EP0868179 A4 EP 0868179A4
Authority
EP
European Patent Office
Prior art keywords
losartan
new use
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96944328A
Other languages
German (de)
English (en)
Other versions
EP0868179A1 (fr
Inventor
Sheila M Cohen
Jeffrey G Werrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603376.6A external-priority patent/GB9603376D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0868179A1 publication Critical patent/EP0868179A1/fr
Publication of EP0868179A4 publication Critical patent/EP0868179A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP96944328A 1995-12-12 1996-12-09 Nouvelle utilisation du losartan Withdrawn EP0868179A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8757 1993-01-25
US875795P 1995-12-12 1995-12-12
GB9603376 1996-02-16
GBGB9603376.6A GB9603376D0 (en) 1996-02-16 1996-02-16 New use for Iosartan
PCT/US1996/019781 WO1997021436A1 (fr) 1995-12-12 1996-12-09 Nouvelle utilisation du losartan

Publications (2)

Publication Number Publication Date
EP0868179A1 EP0868179A1 (fr) 1998-10-07
EP0868179A4 true EP0868179A4 (fr) 2002-01-30

Family

ID=26308746

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96944328A Withdrawn EP0868179A4 (fr) 1995-12-12 1996-12-09 Nouvelle utilisation du losartan

Country Status (4)

Country Link
EP (1) EP0868179A4 (fr)
JP (1) JP2000501736A (fr)
CA (1) CA2238975A1 (fr)
WO (1) WO1997021436A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
EP0855392A3 (fr) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Hétérocycles à cinq chaínons contenant des substituants biphénylylsulphoniques, leur procédé de préparation, leur utilisation comme médicament ou agent diagnostique ainsi que médicament les contenant
IT1295405B1 (it) * 1997-09-30 1999-05-12 Merck Sharp & Dohme Italia S P Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di
AU742506B2 (en) * 1997-10-17 2002-01-03 Eurogene Limited The use of inhibitors of the renin-angiotensin system
GB2337701A (en) * 1998-05-26 1999-12-01 United Medical And Dental Schools Of Guys St Thomas Hospitals Treatment of ischemia with an angiotensin II antagonist
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
AU2003290699B2 (en) * 2002-11-13 2009-08-27 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
US7875624B2 (en) 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
FR2884145A1 (fr) * 2005-04-06 2006-10-13 Flamel Technologies Sa Forme pharmaceutique orale de losartan
JP2008530185A (ja) * 2005-02-21 2008-08-07 フラメル・テクノロジー ロサルタンの経口医薬剤形態
CA2608171C (fr) 2005-05-13 2014-02-04 Novartis Ag Utilisation de composes de quinolinone pour le traitement de cancers pharmacoresistants
KR101817986B1 (ko) * 2009-06-25 2018-01-16 진양제약주식회사 카르복시로자탄을 함유하는 약학 조성물 및 이의 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565485A (en) * 1993-03-19 1996-10-15 Merck & Co., Inc. Biphenyl compounds useful or endothelin antagonists
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CAPASSO ET AL.: "Efficacy of ACE inhibition and AT1 receptor blockade on cardiac pump performance after myocardial infarction in rats", J. CARDIOVASC. PHARMACOL., vol. 23, 1994, pages 584 - 593, XP001033935 *
FLEETWOOD G ET AL: "INVOLVEMENT OF THE RENIN ANGIOTENSIN SYSTEM IN ISCHEMIC DAMAGE AND REPERFUSION ARRHYTHMIAS IN THE ISOLATED PERFUSED RAT HEART", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 17, no. 3, 1991, pages 351 - 356, XP001029360, ISSN: 0160-2446 *
IZUMI HISAKO ET AL: "Effects of BIBR-277, an angiotensin II type 1 receptor antagonist, on stunned myocardium in dogs.", CORONARY ARTERY DISEASE, vol. 7, no. 10, 1996, pages 775 - 779, XP001033778, ISSN: 0954-6928 *
SCHIEFFER ET AL.: "Comparative effects of chronic ACE inhibition and AII type1 receptor blockade on cardiac remodeling after myocardial infarction in the rat", CIRCULATION, vol. 89, 1994, pages 2273 - 2282, XP001033870 *
See also references of WO9721436A1 *
WERRMANN JEFFREY G ET AL: "Comparison of effects of angiotensin-converting enzyme inhibition with those of angiotensin II receptor antagonism on functional and metabolic recovery in postischemic working rat heart as studied by (31P) nuclear magnetic resonance.", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 24, no. 4, 1994, pages 573 - 586, XP001029379, ISSN: 0160-2446 *
YOSHIYAMA ET AL.: "cardioprotective effect of the AII type 1 receptor antagonisr TCV-116 on ischemia-reperfusion injury", AMERICAN HEART JOURNAL, vol. 128, 1994, pages 1-6, XP001029664 *
YOSHIYAMA MINORU ET AL: "Protective effect of pretreatment with angiotensin II type I receptor antagonist on the ischemia-reperfused myocardium.", CIRCULATION, vol. 88, no. 4 PART 2, 1993, 66th Scientific Sessions of the American Heart Association;Atlanta, Georgia, USA; November 8-11, 1993, pages I474, XP001029391, ISSN: 0009-7322 *
ZWEIER JAY L ET AL: "Angiotensin II receptor blockade decreases neutrophil-mediated injury in the postischemic heart.", FASEB JOURNAL, vol. 9, no. 4, 1995, Experimental Biology 95, Part II;Atlanta, Georgia, USA; April 9-13, 1995, pages A844, XP001029375, ISSN: 0892-6638 *

Also Published As

Publication number Publication date
WO1997021436A1 (fr) 1997-06-19
EP0868179A1 (fr) 1998-10-07
JP2000501736A (ja) 2000-02-15
AU704841B2 (en) 1999-05-06
AU1416497A (en) 1997-07-03
CA2238975A1 (fr) 1997-06-19

Similar Documents

Publication Publication Date Title
MA23800A1 (fr) Nouvelle composition
NO982850D0 (no) Ny syntese
EP0868179A4 (fr) Nouvelle utilisation du losartan
EP0783203A4 (fr) Convertisseur de puissance en pont
MA23794A1 (fr) Utilisation de phenylcyclohexylcarboxamides
FR2742661B1 (fr) Nouvelle utilisation de compositions contenant de la nacre
EP0795562A4 (fr) Nouvelle oxyntomoduline
FI952727A0 (fi) Koppling foer drivanordning vid en utbredningsvals
MA23799A1 (fr) Nouvelle composition
FR2732894B1 (fr) Nouvelle utilisation de composes agonistes beta9-adrenergiques
DE59600766D1 (de) Flüssigkeitsringverdichter
FI953319A0 (fi) Dimetyylinaftaleenin valmistus
FI1830U1 (fi) Kaepp foer gaong pao is
FI1921U1 (fi) Vaermeaggregat foer smaeltning av is pao fordonsfoenster
FR2734482B1 (fr) Nouvelle utilisation de composes agonistes beta3-adrenergiques
KR970003380U (ko) 전주 보호구
NO974941D0 (no) Ny anvendelse av (S)-adenosyl-L-metionin(SAMe)
FI2230U1 (fi) Anordning foer dragning av elledningar pao hyllor
KR970026141U (ko) 전화기의 사용내력 출력장치
FIU950484U0 (fi) Anordning foer styrning av en baot pao baetstaell
KR970011853U (ko) 새로운 형태의 메리야스
UA1112S (uk) Мікро-еом широкого призначення
FI953754A0 (fi) Foerfarande foer sammanfogning av byggnadsdelar vid varandra
FI962394A0 (fi) Hjaelpmedel foer anvaendning vid kontroll av sjaelvlaosande brunnslocks laosningsingrepp
FI952897A0 (fi) Foerfarande foer framstaellning av tryckmoenster vid serigrafi

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980713

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20011217

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20020405

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040422